Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168175 | 0.94 | POLB (0.48) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1168324 | 0.87 | AXL (0.51) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1167917 | 0.83 | KDM4E (0.46) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1167198 | 0.81 | POLB (0.48) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1168102 | 0.76 | MAPT (0.52) | HPGDSMN1; SMN2ALDH1A1NPC1JAK2 | |
| SCHEMBL1167935 | 0.75 | ALDH1A1 (0.50) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1167241 | 0.75 | MAPT (0.42) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1168941 | 0.72 | NPC1 (0.52) | KDM4ESMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL1167566 | 0.69 | MAPT (0.46) | KDM4ESMN1; SMN2ALDH1A1NPC1MAPT | |
| SCHEMBL1167493 | 0.69 | KDM4E (0.46) | HPGDPOLBKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-1922310-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007030680-A2 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | HPGD 3210/4885POLB 3121/4885KDM4E 4332/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | HPGD 3260/4885POLB 4096/4885KDM4E 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.